Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Cancer Res. 2019 Dec 16;80(4):771–783. doi: 10.1158/0008-5472.CAN-19-1145

Figure 6.

Figure 6.

ITGB4-targeted immunotherapy reduced the number of ALDHhigh/ITGB4high CSCs. Flow cytometric proportions of ALDHhigh 4T1 (A) and SCC7 (B) cells in residual tumor subjected to treatment as indicated. Frequencies of ITGB4-expressing ALDHhigh and ALDHlow 4T1 (C) and SCC7 (D) cells from residual tumors treated as indicated. The co-expression of ALDH and ITGB4 in residual 4T1 tumors (E) and SCC7 tumors (F). The number of ALDHhigh/ITGB4high residual 4T1 (E) and SCC7 (F) cells were significantly reduced, particularly after combined treatment of DC-vaccine plus anti-PD-L1. Results of flow cytometry were representative of two separate experiments performed.